Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine

Valneva announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.

  • If approved, IXCHIQ® will become the first vaccine available in the EU against the chikungunya virus (CHIKV)
  • Decision on EU marketing authorization expected in the third quarter of 2024

Read more